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Abstract
Background: Hungry bone syndrome (HBS) is an important postoperative complication after parathyroidectomy
for severe secondary hyperparathyroidism (SHPT). There is, however, little data in the literature on its detailed
clinical course, and the associated risk factors remain controversial.
Methods: We did a single-center retrospective study on 62 consecutive dialysis patients who underwent total
parathyroidectomy for SHPT to examine the risk factors, clinical course and outcome. Data on demographic
characteristics, perioperative laboratory parameters including serum calcium, phosphate, alkaline phosphatase
(ALP) and parathyroid hormone (PTH), drug treatment for SHPT and operative details of parathyroidectomy were
collected.
Results: Seventeen (27.4%) patients developed severe postoperative hypocalcemia with HBS. The serum calcium
dropped progressively while serum ALP rose after operation until 2 weeks later when serum calcium reached
the trough and serum ALP peaked. Serum phosphate also fell but stabilized between 4 and 14 days. The total
postoperative calcium and vitamin D supplementation was significantly larger, and hospital stay was significantly
longer in the group with HBS as compared with those without HBS. Young age, high body weight, high
preoperative ALP level, and low preoperative calcium level independently predicted the development of HBS
while preoperative PTH and use of cinacalcet or paricalcitol did not.
Conclusion: HBS was common after total parathyroidectomy in patients with SHPT, and it is important to closely
monitor the postoperative serum calcium, phosphate and ALP levels in the following 2 weeks, especially for those
at risk. The implications of our findings on perioperative management are discussed.
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Background
Secondary hyperparathyroidism (SHPT) is a common
complication of chronic kidney disease (CKD), which
might ultimately develop in nearly all patients with
end-stage renal disease (ESRD) [1]. Despite aggressive
medical therapy, parathyroidectomy continues to be ne-
cessary in those patients with severe SHPT. Hypocalcae-
mia is the most common medical complication following
parathyroidectomy, which could be severe and prolonged
in some situations, where a poorly defined entity called
“hungry bone syndrome” (HBS) has been used to describe
this phenomenon [2].
HBS was first described in 1948 in patients with pro-
longed hypocalcaemia after parathyroidectomy for pri-
mary hyperparathyroidism (HPT) [2]. Old age, size of
resected parathyroid glands, preoperative serum parathy-
roid hormone (PTH) level, preoperative serum alkaline
phosphatase (ALP) level, and serum urea nitrogen concen-
tration were found to be risk factors [3–6]. Nevertheless,
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the situation in SHPT should be more complicated, to
which the above findings in HPT might not be applicable.
Renal osteodystrophy in patients with ESRD encom-
passes a wide range of bone abnormalities including
osteitis fibrosa, adynamic bone disease, osteomalacia,
and mixed uremic osteodystrophy [7]. The exact bone
abnormality present in individual dialysis patients,
which directly affects the bone and metabolic response
as well as postoperative course, is highly variable and
could not be reliably predicted by serum PTH level [7, 8].
In this context, there is, indeed, little data in the literature
concerning the clinical course and risk factors of severe
prolonged hypocalcemia or hungry bone syndrome in
ESRD patients with SHPT undergoing total parathyroid-
ectomy. In particular, there have been some new drugs, in-
cluding paricalcitol and cinacalcet, recently available for
the treatment of SHPT, and it would be interesting to
know whether these drugs would impact on the postoper-
ative course and development of HBS. We therefore did a
study to examine the clinical course and risk factors of
HBS in a cohort of dialysis patients undergoing total para-
thyroidectomy. The findings could be of substantial help
in the prevention of HBS and perioperative management
in this group of patients.
Methods
It was a retrospective study on 62 consecutive dialysis pa-
tients who underwent parathyroidectomy because of
SHPT between January 1, 2004, and February 28, 2014, in
a regional hospital with a program of about 300 prevalent
peritoneal dialysis (PD) and 100 hemodialysis (HD) pa-
tients. Indications for parathyroidectomy included: severe
SHPT (persistent PTH > 85 pmol/L) refractory to medical
therapy with calcitriol, or vitamin D analogs, or calcimi-
metics, or a combination of calcimimetics and calcitriol or
vitamin D analogs at maximal doses tolerated by individ-
ual patients; severe SHPT associated with hypercalcaemia
(total calcium corrected for albumin concentration >
2.60 mmol/L) and/or hyperphosphataemia (>2.0 mmol/L)
precluding further approaches with medical therapy; and
calciphylaxis associated with SHPT. The study was ap-
proved by Hong Kong Hospital Authority Kowloon West
Cluster Clinical Research Ethics Committee.
The medical records were reviewed and data includ-
ing patient gender, age at the time of surgery, and op-
erative-, laboratory-, medication-, and dialysis-related
data were collected. The serial results of the following
laboratory parameters preoperatively and, for multiple
time points, postoperatively were identified: hemoglobin,
serum albumin, calcium, phosphate, alkaline phosphatase
(ALP), and intact parathyroid hormone (PTH) levels.
Except for the early postoperative period when frequent
and close monitoring of serum calcium was required,
blood sampling was performed immediately before the
commencement of individual dialysis session in HD pa-
tients. In addition, detailed information about preoperative
medications, including daily doses of phosphate-binding
drugs, active vitamin D analogs and calcimimetics were re-
corded. For active vitamin D analogs and calcimimetics,
the exposure to such agents was counted only if the pa-
tients had taken the drug for 30 days or more within the
90-day period preceding the surgery. Cumulative doses of
calcium and vitamin D supplements at 14 days, 1 month,
3 months and 12 months after surgery were calculated.
Hungry Bone Syndrome was defined as profound and
prolonged hypocalcaemia with corrected serum calcium
level of 2.1 mmol/L or below lasting for 4 or more days,
that occurred anytime within 1 month following para-
thyroidectomy, despite standard postoperative support-
ive treatment of our unit. Patients developing HBS
according to the definition were compared with those
without HBS in terms of baseline characteristics, clinical
course and length of hospitalization, and multivariate ana-
lysis was performed to evaluate the effect of age, sex, body
weight, vintage on dialysis, Kt/V, size of the resected para-
thyroid glands, preoperative laboratory parameters includ-
ing serum PTH, ALP, calcium, phosphate, hemoglobin
and albumin as well as SHPT drug treatment for the
development of HBS.
Surgical procedure
All patients underwent bilateral neck exploration with an
attempt to identify all parathyroid glands. When four or
more glands were identified at the time of surgery, total
parathyroidectomy was intended without doing any auto-
transplantation. If fewer than four glands were found, all
identifiable parathyroid glands were removed.
Perioperative treatment strategy
All patients undergoing parathyroidectomy were started
on oral alfacalcidol 2 micrograms twice daily for 2 days
before surgery if they were not receiving any form of
active vitamin D analog before the surgery. After sur-
gery, all patients received a normal calcium dialysis
bath. All patients were started on intravenous calcium
infusion at a rate of 2720 mg elemental calcium (Ca)/
day (as mixture of 50 ml 10% calcium chloride solution
and 450 ml normal saline solution). Serum calcium
levels were monitored every 6 h starting from the time
immediately after surgery. If serum calcium level was
2.1 mmol/L or below, an extra 10 ml of 10% calcium
chloride solution (272 mg elemental Ca) was given. If
serum calcium level was 2.4 mmol/L or above, intra-
venous calcium chloride infusion was stopped for 6 h
and then restarted. Cinacalcet or paricalcitol therapy
was stopped if present. When they were fully awake,
patients were prescribed with oral calcium supplements
and vitamin D analogs (alfacalcidol or calcitriol) with
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the dosage titrated against the serum calcium levels to
allow cessation of calcium infusion. The frequency of
serum calcium level monitoring and the dosage of
intravenous calcium infusion were adjusted by the at-
tending physician the next day after operation. Patients
were discharged when calcium levels remained stable in
the normal range.
Statistical analysis
Statistical analyses of collected data were performed
using SPSS version 21.0. Data were expressed as mean
± SD if normally distributed, or median and interquar-
tile range otherwise. For univariate analysis, categorical
variables were compared using the chi-square test or
Fisher’s exact test where appropriate. Continuous variables
were compared using independent samples T-test or
Mann-Whitney U test for data of non-normal distribution.
Variables with a p value of <0.05 in univariate analysis
were entered into the multiple logistic regression model.
Variables with p < 0.05 (2 tailed) were considered statisti-
cally significant.
Results
Baseline characteristics, surgical procedures, parathyroid
pathology
There were 46 female and 16 male patients with a mean
age of 52.6 ± 12.2 years (Table 1). There was no predom-
inant primary renal diagnosis in these patients. At the
time of surgery, 17 (27.4%) patients were receiving HD
and 45 (72.6%) were receiving PD. Mean vintage on dia-
lysis was 5.9 ± 2.6 years.
Within 90 days preoperatively, 31 (50%) patients received
one or more phosphate binders, 23 (37.1%) received active
vitamin D sterols (three had calcitriol, 12 had alfacalcidol,
eight had paricalcitol), and 14 (22.6%) received calcimi-
metics (cinacalcet).
48 (77.4%) patients had all four glands identified and
resected during surgery. The pathology revealed parathy-
roid hyperplasia in 95.2% of cases.
Post-operative bone mineral metabolism and hungry
bone syndrome
The mean serum calcium level of the 62 patients de-
creased from 2.57 ± 0.21 mmol/L preoperatively to 2.47
± 0.29 mmol/L on postoperative day 1 (p <0.0001).
There were 17 patients (27.4%) who developed severe
hypocalcemia with the onset of hypocalcaemia ranging
from day 1 to day 14 after surgery fulfilling the diagno-
sis of HBS according to our study definition (Fig. 1).
However, they all suffered no symptom of hypocalcae-
mia. While the serum calcium levels of patients without
HBS appeared to stabilize after the first few days, the
fall of serum calcium in patients with HBS tended to
last longer with the trough occurring at about 2 weeks
Table 1 Baseline demographics and clinical data
No. of patients 62
Gender (M:F) 16:46
Age at time of surgery (years) 52.6 ± 12.2
Body weight (kg) 52.9 (46–65)
Underlying renal diagnosis, no. of patients (%)
Diabetic nephropathy 9 (14.5)
Hypertensive nephropathy 10 (16.1)
Polycystic kidney 4 (6.5)
Glomerulonephritis 20 (32.2)
Unknown 19 (30.6)
RRT at time of surgery
PD 45 (72.6)
HD 17 (27.4)
Duration of dialysis (years) 5.9 ± 2.6
Kt/V (weekly) 2.31 ± 0.9
Preoperative serum biochemistry
iPTH–peak (pmol/L) 170 (131–221)
iPTH–immediately before operation (pmol/L) 156.5 (122–215)
ALP–peak (IU/L) 309.5 (192–511)
ALP–immediately before operation (IU/L) 261 (161–447)
Calciuma (mmol/L) 2.57 ± 0.21
Phosphate (mmol/L) 2.28 ± 0.65
Albumin (g/L) 31 ± 5
Haemoglobin (g/dL) 9.9 ± 1.5
Preoperative drug treatment
Phosphate binders (n = 31)
Calcium carbonate (n = 21) (mg/day) 2904.8 ± 1921.1
Aluminium hydroxide (n = 4) (mg/day) 1400.0 ± 632.5
Lanthanum (n = 3) (mg/day) 1083.3 ± 381.9
Sevelamer (n = 4) (mg/day) 2100.0 ± 1194.4
Active vitamin D (n = 23)
Calcitriol (n = 3) (μg/week) 1.00 ± 0.50
Alfacalcidol (n = 12) (μg/week) 1.17 ± 0.83
Paricalcitol (n = 8) (μg/week) 24.00 ± 14.30
Cinacalcet (n = 14) (mg/day) 35.7 ± 16.2
Surgical procedure, no. of patients (%)
4 glands resected 48 (77.4)
Less than four glands resected 14 (22.6)
Weight of resected parathyroid tissue (g) 2.56 ± 1.56
Pathology of parathyroid tissue, no. of patients (%)
Hyperplasia 59 (95.2)
Adenoma 3 (4.8)
Abbreviations: PD Peritoneal dialysis, HD Hemodialysis, iPTH intact parathyroid
hormone, ALP alkaline phosphatase
aAdjusted by serum albumin level
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after the operation. The serum calcium levels of patients
with HBS remained significantly lower throughout the fol-
lowing up period up to 1 year after operations when com-
pared with patients without HBS.
The mean serum phosphate level of the 62 patients
decreased from 2.28 ± 0.65 mmol/L preoperatively to
1.75 ± 0.54 mmol/L on postoperative day 1 (p < 0.0001).
The serum phosphate level tended to stabilize between 4
and 14 days after the operation. Hypophosphataemia
with serum phosphate level of < 0.8 mmol/L was ob-
served in 24 (38.7%) patients within 1 month following
parathyroidectomy. There was no significant difference
in the serum phosphate level between patients with and
without HBS. The change in serum phosphate level over
time was shown in Fig. 2.
Generally, serum ALP level increased progressively
after surgery in both groups, attaining their peak levels
at 2 weeks postoperatively and then decreased gradually
(Fig. 3). By 3 months, 54.8% of all patients had their
ALP level fall within the normal limit, and 1 year after
surgery 88.7% of them had the ALP level normalized. In
addition to having a higher preoperative level, patients
with HBS also showed a significantly higher serum ALP
level at day 5, day 7 and 1 month after the operation as
compared with patients without HBS.
77.4% of the patients had their iPTH levels normalized
after surgery within 1 week’s time. At 1-year follow-up,
12 (19.4%) patients had residual/ recurrent hyperpara-
thyroidism as evidenced by PTH levels persistently
above the normal reference range.
Comparison between patients with or without HBS
Calcium and vitamin D supplementation
Table 2 summarized the results on postoperative use of
calcium and vitamin D supplementation in the 62 patients
divided into the two outcome groups. Average daily doses
of calcium supplementation were significantly higher in
the group with HBS compared to the group without HBS
up to 1 year postoperatively. Similarly, average daily doses
of vitamin D supplementation postoperatively were higher
in HBS group as compared with the group without HBS
throughout the study period.
For patients who received active vitamin D analogs pre-
operatively, the requirement of calcium and vitamin D sup-
plementation after surgery tended to be lower than those
who did not receive active vitamin D analogs, but the dif-
ference did not reach statistical significance (Table 3a).
For patients who received cinacalcet preoperatively, the
requirement of calcium and vitamin D supplementation
after surgery appeared to be higher than those who did
Fig. 1 Serum calcium level before and after parathyroidectomy. Abbreviations: Preop, preoperative; POD, days of operation; POM, months after
operation; POY, years after operation; HBS, hungry bone syndrome; CI, confidence interval. Solid line: patients with HBS; Dotted line; patients
without HBS
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Fig. 3 Serum ALP level before and after parathyroidectomy. Abbreviations: Preop, preoperative; POD, days of operation; POM, months after
operation; POY, years after operation; HBS, hungry bone syndrome; ALP, alkaline phosphatase; CI, confidence interval. Solid line: patients with HBS;
Dotted line; patients without HBS
Fig. 2 Serum phosphate level before and after parathyroidectomy. Abbreviations: Preop, preoperative; POD, days of operation; POM, months after
operation; POY, years after operation; HBS, hungry bone syndrome; CI, confidence interval. Solid line: patients with HBS; Dotted line; patients without HBS
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not receive cinacalcet, but the difference did not reach
statistical significance (Table 3b).
Duration of hospitalization
Length of hospital stay was significant longer in HBS
group compared with the group without HBS (15.4 ±
6.6 days vs 10.2 ± 2.3 days, p = 0.007) (Table 2).
Risk factors
Compared with patients without HBS, patients with HBS
were of younger age (47.5 years vs 54.5 years, p = 0.043),
higher body weight (60.7 kg vs 49.8 kg, p = 0.01), higher
preoperative serum ALP level (415 IU/L vs 221 IU/L, p =
0.008), and lower preoperative serum calcium level
(2.44 mmol/L vs 2.60 mmol/L, p = 0.001) (Table 4). The
proportion of male patients was also higher in HBS group
compared with the group without HBS (47.1 vs 16.7%, p =
0.019). Preoperative use of active vitamin D analogs had
no significant effect on the development of HBS. The pro-
portion of patients with preoperative use of cinacalcet ap-
peared to be higher in HBS group compared with the
group without HBS but the difference did not reach statis-
tical significance (35.3 vs 17.8%, p = 0.141).
With the significant findings in univariate analysis,
factors including gender, age, body weight, serum pre-
operative ALP and serum preoperative calcium levels
were further evaluated using multivariate logistic re-
gression analysis, and it showed that that young age,
high body weight, high preoperative serum ALP level,
and low preoperative serum calcium level independ-
ently predicted the development of HBS (Table 5). Add-
itional analyses forcing preoperative iPTH levels into
the model yielded no change in the results.
Table 2 Calcium and active vitamin D supplementation
following total parathyroidectomy
No HBS HBS p value
Average daily dose of active vitamin Da supplementation (μg)
Postop Day 14 2.04 ± 1.46 2.89 ± 1.96 0.068
Postop Month 1 1.77 ± 1.15 3.20 ± 2.11 0.016
Postop Month 3 1.24 ± 0.78 2.87 ± 2.13 0.006
Postop Year 1 0.65 ± 0.44 2.40 ± 2.13 0.018
Average daily dose of elemental calciumb supplementation (mg)
Postop Day 14 4362.5 ± 3492.8 8551.3 ± 4671.2 <0.001
Postop Month 1 3869.2 ± 3086.0 9119.3 ± 4904.7 <0.001
Postop Month 3 2554.9 ± 1780.3 7896.9 ± 5230.1 0.001
Postop Year 1 1503.5 ± 923.2 5545.7 ± 4642.9 0.005
Hospital stay (days) 10.2 ± 2.3 15.4 ± 6.6 0.007
aCalcitriol or alfacalcidol
bIn the form of oral calcium carbonate tablets (40% elemental calcium)
Table 3 Calcium and active vitamin D supplementation following total parathyroidectomy
No preoperative use of active vitamin D Preoperative use of active vitamin D p value
a. Average daily dose of active vitamin Da supplementation (μg)
Postop Day 14 2.33 ± 1.74 2.18 ± 1.50 0.729
Postop Month 1 2.19 ± 1.68 2.12 ± 1.47 0.876
Postop Month 3 1.73 ± 1.56 1.61 ± 1.34 0.760
Postop Year 1 1.20 ± 1.71 0.91 ± 1.00 0.416
Average daily dose of elemental calciumb supplementation (mg)
Postop Day 14 6070.3 ± 4588.2 4562.7 ± 3790.0 0.179
Postop Month 1 5760.1 ± 4607.1 4543.5 ± 3790.4 0.289
Postop Month 3 4455.6 ± 4040.3 3280.5 ± 3624.0 0.255
Postop Year 1 2635.2 ± 2591.4 2328.4 ± 3733.1 0.713
No preoperative use of cinacalcet Preoperative use of cinacalcet
b. Average daily dose of active vitamin Da supplementation (μg)
Postop Day 14 2.14 ± 1.61 2.73 ± 1.74 0.238
Postop Month 1 2.03 ± 1.55 2.64 ± 1.69 0.211
Postop Month 3 1.58 ± 1.43 2.03 ± 1.62 0.320
Postop Year 1 0.96 ± 1.11 1.64 ± 2.54 0.387
Average daily dose of elemental calciumb supplementation (mg)
Postop Day 14 5421.4 ± 4243.3 5818.4 ± 4424.1 0.761
Postop Month 1 5180.7 ± 4263.0 5748.0 ± 4693.8 0.670
Postop Month 3 3864.0 ± 3413.5 4553.7 ± 5381.1 0.565
Postop Year 1 2270.6 ± 1909.5 3551.9 ± 5541.6 0.446
aCalcitriol or alfacalcidol
bIn the form of oral calcium carbonate tablets (40% elemental calcium)
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Discussion
Although there are a few retrospective studies in the lit-
erature examining the problem of post-operative hypocal-
cemia in dialysis patients undergoing parathyroidectomy,
there was marked heterogeneity in the case definition and
reported incidence ranging from 27.8 to 72%. Most
studies merely focused on individual aspect such as the
occurrence of early hypocalcemia immediately after the
operation whereas other studies addressed the problem
from other perspectives such as the length of hospital stay
after operation, hospital readmission and total calcium re-
quirement [9–13]. Since these studies just concentrated
on a particular area in the postoperative course, the data
Table 4 Clinical characteristics of patients with and without HBS following total parathyroidectomy
No HBS HBS p value
No. of patients 45 17 -
Male gender 8 (16.7%) 8 (47.1%) 0.019
Age (years) 54.5 ± 12.5 47.5 ± 10.2 0.043
Body weight (kg) 49.8 (44.9–61.6) 60.7 (50.4–71.2) 0.01
PD (%) 77.8 58.8 0.136
Duration of dialysis (years) 5.9 ± 2.3 6.0 ± 3.3 0.904
Kt/V (weekly) 2.26 ± 0.80 2.47 ± 1.21 0.439
Preoperative serum biochemistry
iPTH–peak (pmol/L) 164 (123–213) 189 (151–243) 0.144
iPTH–immediately before operation (pmol/L) 154 (117–211) 183 (137–221) 0.237
ALP–peak (IU/L) 250 (178–496) 415 (226–738) 0.051
ALP–immediately before operation (IU/L) 221 (149–397) 415 (221–727) 0.008
Calciuma (mmol/L) 2.62 ± 0.18 2.44 ± 0.23 0.001
Phosphate (mmol/L) 2.26 ± 0.58 2.34 ± 0.81 0.637
Albumin (g/L) 30 ± 5 32 ± 5 0.220
Haemoglobin (g/dL) 10.0 ± 1.4 9.5 ± 1.7 0.242
Preoperative drug treatment
Use of phosphate binders 21 (46.7%) 10 (58.8%) 0.393
Calcium carbonate 15 (33.3%) 6 (35.3%) 0.884
Aluminium hydroxide 1 (2.2%) 3 (17.6%) 0.059
Lanthanum 2 (4.4%) 1 (5.9%) 1.000
Sevelamer 4 (8.9%) 0 0.568
Use of active vitamin D 16 (35.6%) 7 (41.2%) 0.683
Calcitriol 1 (2.2%) 2 (11.8%) 0.180
Alfacalcidol 9 (20%) 3 (17.6%) 1.000
Paricalcitol 6 (13.3%) 2 (11.8%) 1.000
Use of cinacalcet 8 (17.8%) 6 (35.3%) 0.141
4 glands resected 35 (77.8%) 13 (76.5%) 0.913
Weight of resected parathyroid tissue (g) 2.42 ± 1.63 2.93 ± 1.32 0.254
Parathyroid hyperplasia 43 (95.6%) 16 (94.1%) 1.000
iPTH at postoperative week 1 (pmol/L) 2.1 (0.5–6.6) 0.7 (0.4–3.9) 0.174
Abbreviations: PD Peritoneal dialysis, iPTH Intact parathyroid hormone, ALP Alkaline phosphatase
a Adjusted by serum albumin level






Body Weight 1 kg 1.06 1.007–1.12 0.027
Preoperative
serum calcium
1 mmol/L 0.005 0.0001–0.332 0.013
Age 1 year 0.923 0.86–0.99 0.035
Preoperative ALP 1 IU/L 1.004 1.0–1.007 0.044
Abbreviations: ALP Alkaline phosphatase, HBS Hungry bone syndrome
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might not be able to reflect the whole situation. In
addition, parathyroid procedures were rather variable
in these studies. The majority underwent subtotal para-
thyroidectomy or total parathyroidectomy with auto-
transplantation while total parathyroidectomy merely
accounted for a minority. Indeed, there has not been
any study that could clearly delineate the postoperative
course in patients with total parathyroidectomy for
SHPT.
In this context, this study examined multiple aspects
related to the postoperative care in patients suffering from
SHPT undergoing total parathyroidectomy without auto-
transplantation. They included serial changes in serum
calcium, phosphate and alkaline phosphatase levels, cal-
cium and active vitamin D requirement and length of
hospitalization in addition to risk factor identification for
postoperative occurrence of HBS. Indeed, this study
showed that in patients undergoing total parathyroidec-
tomy, although the serum calcium level and phosphate
level tended to fall immediately after the operation, there
might be a delay up to 2 weeks after the operation before
it reached its lowest level. At the same time, serum ALP
level also increased progressively after the operation,
reflecting the state of increased bone formation [14, 15],
and peaked at week 2. These findings should carry import-
ant implications. First, the severity of hypocalcemia and
demand of calcium replacement resulting from acceler-
ated bone formation might not be fully reflected by the
serum calcium level early after operation. In other words,
patients might develop severe hypocalcemia in the later
time despite a modest drop in serum calcium early
postoperatively. Therefore, patients undergoing total para-
thyroidectomy should have their serum calcium and phos-
phate levels closely monitored in the following 2 weeks to
safeguard against the development of severe hypocalcemia
and to provide guidance on the intensity of calcium sup-
plementation. At the same time, it appeared that the rise
of serum alkaline phosphate correlated well with the de-
cline in serum calcium and probably increasing demand
of calcium replacement. Serum ALP level might therefore
serve as a biomarker indicating the intensity of bone for-
mation and the likely calcium requirement of individual
patients. In practical terms, a rising serum alkaline phos-
phatase might portend an increasing demand for calcium
supplementation and should prompt for a dose escalation
whereas a declining serum ALP level would warrant con-
sideration of dose tapering in active vitamin D and cal-
cium to avoid overzealous replacement and inadvertent
hypercalcemia.
Second, this postoperative calcium dynamic with de-
layed drop in serum calcium level also challenges the
validity of those case definition adopted by some previous
studies in examining the problem, which solely focused
on serum calcium level immediately after operation. In
contrast, by including all those cases having profound
and prolonged hypocalcaemia lasting for 4 days or
more that occurred anytime within 1 month following
parathyroidectomy, it is highly unlikely that any case of
significant postoperative hypocalcemia would have been
missed and misclassified in this study. In other words,
we believe that our definition of HBS in this study
should be appropriate which could allow us to identify
a particular group of patients who would likely require
intensive monitoring and aggressive calcium supple-
mentation. It follows that the risk factors found in this
study should also be highly relevant and be of help in
accurately identifying those high risk individuals.
With our case definition, hungry bone syndrome (HBS)
was found to be present in 27.4% of cases in this study.
The risk factors predisposing to its development were
young age, high body weight, high preoperative ALP level,
and low preoperative serum calcium level. Young age and
low preoperative calcium have been reported in previous
individual case series which employed various different
case definitions [9–11]. The role of preoperative serum
ALP level, however, remained controversial. In a case
series, high preoperative ALP was shown to be predictive
of hypocalcemic problem as being represented by a pro-
longed hospital stay, whereas protective effect was found
in another study which focused on early hypocalcemia
within 24 h after operation [9, 13]. On the other hand,
heavy body weight was, for the first time, being identified
as a risk factor. While the exact underlying mechanism re-
mains unknown, it is plausible that patients with high
body weight might have a higher bone mass and hence
higher total calcium deficit [16, 17].
Preoperative PTH level was not shown to be a risk
factor in the current study. There are a few possible
explanations for this. First, uraemic state is associated
with resistance of bone cells to the actions of PTH
[18–20], and the relationship between serum iPTH
levels and degree of bone remodeling is not always
maintained. Second, iPTH assay not only measures the
level of biologically active intact PTH (1-84), but also
shows cross-reactivity with some smaller N-terminally
truncated PTH fragments which have bone action oppos-
ite to intact PTH (1-84) [18–20].
No significant difference was observed between pa-
tients with or without receiving active vitamin D sterols
such as paricalcitol or cinacalcet preoperatively in terms
of the risk of HBS and postoperative calcium require-
ment. This could either be due to our small sample size
or be ascribed to an indirect effect of these drugs on
bone healing instead of any direct effect on HBS. Never-
theless, with medications such as paricalcitol shown to
have significant effect in suppressing serum ALP in the
literature, it is possible that intensive treatment with this
type of agents before operation might help mitigate the
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risk of severe postoperative hypocalcemia [21]. On the
other hand, with low serum calcium being a risk factor
for HBS, overzealous treatment with cinacalcet pre-
operatively should probably be avoided.
The present study had several limitations. First, it was
retrospective and observational in nature. Thus, the re-
sults were subject to possible selection bias and limited
by suboptimal data collection. Second, the sample size
was relatively small and potential significant associations
among variables could have been masked. A formal mul-
ticenter registry would provide more accurate estimate
of epidemiology and better understanding of clinical
features of HBS following parathyroidectomy in renal
SHPT in our region. Third, due to the heterogeneous
definitions of significant postoperative hypocalcemia or
HBS, one must be cautious when comparing the results
of the present study to other similar studies.
In addition, patients receiving PD and intermittent
HD were pooled into a single study population in this
study, where pre-dialysis serum concentrations of indi-
vidual parameters in HD patients were compared with
their PD counterparts being obtained by random blood
sampling. With inherent fluctuations in serum concen-
trations, there might be a concern that pre-dialysis
serum concentrations of dialyzable uremic retention
molecules, in particular, phosphorus in patient on inter-
mittent HD might not truly reflect the overall exposure,
which could potentially affect the validity of compari-
son. For example, the time-averaged serum concentra-
tions of phosphorus in HD patients were significantly
lower despite having the pre-dialysis concentrations
comparable with midmorning concentrations of PD
[22, 23]. Nevertheless, with similar proportions of HD
and comparable preoperative serum phosphate levels in
patients with or without HBS in this study, we believe
that it should not impact significantly on the results
and our univariate and multivariate analyses in risk fac-
tor identification should remain valid.
Conclusion
HBS could be common after total parathyroidectomy.
Serum calcium tended to fall soon after a successful
total parathyroidectomy but the occurrence of severe
hypocalcemia could be delayed up to 2 weeks after the
operation. Patients should have their serum calcium,
phosphate and ALP levels closely monitored in the fol-
lowing 2 weeks, especially for those at risk. Hopefully,
with a better understanding of postoperative course and
improvement of perioperative management, the occur-
rence of severe hypocalcemia could be avoided and any
adverse consequence could be minimized.
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